CAREDX, INC.
Moat Score — CareDx, Inc.
Total Moat Score
16 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | CareDx's AlloSure/AlloMap franchise carries strong clinical validation, published outcomes data, and a newly finalized Medicare Local Coverage Determination behind it, giving it durable regulatory and evidence-based intangible assets that are difficult and time-consuming for competitors to replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Running roughly 200,000 tests annually across a centralized lab platform gives CareDx meaningful scale economics versus smaller transplant-diagnostics entrants, though it does not have a structural input-cost advantage over well-funded rivals like Natera. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As the entrenched standard of care with Medicare coverage now codified via LCD, CareDx has real ability to sustain testing volumes and pricing, though Medicare policy and payer negotiations still bound how much pricing power it can exercise. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | There is a mild data/evidence network effect — more tests performed strengthen the clinical evidence base supporting adoption — but this is not a classic multi-sided network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Once a transplant center standardizes its monitoring protocol on AlloSure/AlloMap and integrates CareDx's Ottr workflow software (used in 170+ centers) and specialty pharmacy services, switching to a competitor requires re-validating clinical workflows and risking care continuity, creating high real-world stickiness. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Transplant diagnostics is a relatively small, specialized market where CareDx's incumbency and scale make it a suboptimal target for new entrants, though the market is large enough that well-capitalized competitors like Natera and Thermo Fisher continue to push in. |